TMCnet News
Vaccitech Announces Closing of $110.5 Million Initial Public OfferingOXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS. The gross proceeds from the offering were approximately $110.5 million. Vaccitech’s ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol “VACC” on April 30, 2021. All ADSs sold in the offering were offered by Vaccitech. Morgan Stanley, Jefferies, Barclays and William Blair acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering. The Registration Statement on Form S-1 relating to the proposed sale of these securities was filed with the U.S. Securities and Exchange Commission and was declared effective on April 29, 2021. The offering of ADSs was made only by means of a prospectus, copies of which may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Jefferies LLC, Attention: Equity yndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] or telephone at 1-888-603-5847; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Vaccitech plc Vaccitech Media contacts: Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc. Henry Hodge, Vaccitech |